Zacks Research Downgrades Tempest Therapeutics (NASDAQ:TPST) to Hold

Tempest Therapeutics (NASDAQ:TPST) was downgraded by analysts at Zacks Research from a “strong-buy” rating to a “hold” rating in a research report issued to clients and investors on Thursday,Zacks.com reports.

Separately, Wall Street Zen downgraded shares of Tempest Therapeutics from a “hold” rating to a “sell” rating in a research note on Saturday. One research analyst has rated the stock with a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, Tempest Therapeutics currently has a consensus rating of “Reduce”.

Tempest Therapeutics Price Performance

Shares of TPST stock opened at $1.83 on Thursday. The company’s 50-day simple moving average is $1.94 and its two-hundred day simple moving average is $3.35. Tempest Therapeutics has a one year low of $1.50 and a one year high of $12.23. The company has a market capitalization of $26.24 million, a P/E ratio of -0.30 and a beta of -1.75.

Tempest Therapeutics (NASDAQ:TPST) last released its quarterly earnings data on Friday, May 15th. The company reported ($2.53) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.28) by ($2.25). On average, research analysts expect that Tempest Therapeutics will post -1.34 EPS for the current fiscal year.

Insider Activity

In other Tempest Therapeutics news, CEO Matthew Angel acquired 231,482 shares of the company’s stock in a transaction dated Tuesday, March 24th. The shares were purchased at an average cost of $2.16 per share, for a total transaction of $500,001.12. Following the completion of the purchase, the chief executive officer owned 231,482 shares in the company, valued at approximately $500,001.12. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 6.28% of the company’s stock.

Institutional Investors Weigh In On Tempest Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Sabby Management LLC purchased a new stake in Tempest Therapeutics during the fourth quarter valued at approximately $513,000. Vanguard Group Inc. lifted its position in Tempest Therapeutics by 20.8% during the third quarter. Vanguard Group Inc. now owns 162,560 shares of the company’s stock valued at $1,671,000 after acquiring an additional 27,952 shares during the last quarter. Finally, Dimensional Fund Advisors LP purchased a new stake in Tempest Therapeutics during the fourth quarter valued at approximately $33,000. Hedge funds and other institutional investors own 22.52% of the company’s stock.

About Tempest Therapeutics

Tempest Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of small molecule therapies for cancer and immune‐mediated diseases. Leveraging a proprietary drug discovery platform, Tempest advances programs designed to modulate tumor metabolism and enhance antitumor immunity. Its pipeline includes oral, selective inhibitors targeting pathways such as peroxisome proliferator‐activated receptor alpha (PPARα) and salt‐inducible kinase (SIK), with potential applications across solid tumors and hematologic malignancies.

The company’s lead candidate, TPST-1120, is a first‐in‐class PPARα antagonist designed to reprogram the tumor microenvironment by disrupting fatty acid oxidation in immune and cancer cells.